SCHEMBL3984153

SCHEMBL3984153

O=C(O)c1c(NS(=O)(=O)c2cccc3cccnc23)ccc2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.65
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
METAP2 P50579 2/20 0.62
METAP1 P53582 1/20 0.62
GAA P10253 2/20 0.61
SLC16A3 O15427 2/20 0.56
KEAP1 Q14145 1/20 0.56
NFE2L2 Q16236 1/20 0.56
TDP1 Q9NUW8 2/20 0.55
ALDH1A1 P00352 2/20 0.55
POLB P06746 1/20 0.55
SLC40A1 Q9NP59 5/20 0.54
ATM Q13315 1/20 0.53
NFKBIA P25963 1/20 0.52
RELA Q04206 1/20 0.52
BRD4 O60885 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3985999 0.85 METAP2 (0.74) MEN1KMT2AMETAP2METAP1SLC16A3
SCHEMBL29540765 0.84 GAA (0.71) MMP2MEN1KMT2AGAAKEAP1
SCHEMBL22234047 0.84 GAA (0.71) MMP2MEN1KMT2AGAAKEAP1
SCHEMBL5075506 0.82 SLC40A1 (0.66) MMP2MEN1KMT2AGAASLC16A3
SCHEMBL14301393 0.82 MMP2 (0.66) MMP2MEN1KMT2AGAASLC16A3
SCHEMBL3987730 0.81 L3MBTL1 (0.65) MEN1KMT2AMETAP2METAP1GAA
SCHEMBL3981979 0.81 METAP2 (0.67) MMP2METAP2METAP1SLC40A1
SCHEMBL5072751 0.81 MEN1 (0.71) MMP2MEN1KMT2AMETAP2METAP1
SCHEMBL30009657 0.80 GAA (0.73) MMP2MEN1KMT2AGAAKEAP1
SCHEMBL28389279 0.80 GAA (0.73) MMP2MEN1KMT2AGAAKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-04-08 US claimed
US-7491718-B2 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES (US) 2009-02-17 US disclosed
EP-1549613-A1 SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY Abbott Laboratories (US) 2005-07-06 EP disclosed
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity ABBVIE INC. 2004-08-26 US disclosed
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-08-12 US disclosed
WO-2004033419-A1 SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY ABBOTT LABORATORIES (US) 2004-04-22 WO disclosed
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-04-08 US disclosed
WO-1999029670-A2 AMINOCARBONYLTETRALIN AND DIHYDRONAPHTALENE DERIVATES AS THROMBIN INHIBITORS BOEHRINGER INGELHEIM PHARMA KG (DE) 1999-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP MMP2 90/4885MEN1 580/4885KMT2A 647/4885
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP MMP2 90/4885MEN1 580/4885KMT2A 647/4885
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP MMP2 90/4885MEN1 580/4885KMT2A 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.